Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.71 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.64 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | QPCT | Q16769 | 1/20 | 0.64 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.64 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394308 | 0.91 | CYP11B1 (0.83) | CYP11B1CYP11B2ADRA2CCYP19A1TBXAS1 | |
| SCHEMBL7284368 | 0.86 | CYP11B1 (0.73) | CYP11B1CYP11B2CYP19A1TBXAS1CYP1A2 | |
| SCHEMBL27508985 | 0.84 | CYP11B1 (0.51) | CYP11B1CYP11B2ADRA2CCYP19A1TBXAS1 | |
| SCHEMBL30448042 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1TBXAS1 | |
| SCHEMBL3092795 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1TBXAS1 | |
| SCHEMBL860653 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1TBXAS1 | |
| SCHEMBL12299569 | 0.83 | CYP11B1 (0.71) | CYP11B1CYP11B2ADRA2CCYP19A1TBXAS1 | |
| SCHEMBL28802722 | 0.80 | CYP11B1 (0.67) | CYP11B1CYP11B2ADRA2CCYP19A1TBXAS1 | |
| SCHEMBL9747422 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1TBXAS1 | |
| SCHEMBL12205 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-05-09 | — | — | US | disclosed |
| CN-114805341-B | Aromatic heterocyclic compound, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-114805341-A | Aromatic heterocyclic compounds and preparation method and application thereof | 上海翊石医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TLR7, TLR1, TLR8 | CYP11B1 92/4885CYP11B2 122/4885ADRA2C 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.